This review summarises important pharmacological and clinical characteristics of levodopa/benserazide
(Madopar®) in the treatment of Parkinson’s disease. The benefits of commencing levodopa-replacement
therapy early in the disease course and availability of multiple levodopa/benserazide formulations and doses
for the individualization of therapy are also discussed.
Independent expert commentary provided by Dr Paul Clouston and Dr Simon Lewis.
Please login below to download this issue (PDF)